Comparative Pharmacology
Head-to-head clinical analysis: E E S 400 versus ZITHROMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S 400 versus ZITHROMAX.
E.E.S. 400 vs ZITHROMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin, a macrolide antibiotic, binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. At high concentrations, it may also inhibit RNA synthesis.
Azithromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by preventing translocation of peptides. It also has immunomodulatory and anti-inflammatory effects.
Erythromycin ethylsuccinate 400 mg orally every 6 hours. For severe infections, up to 4 g/day in divided doses.
500 mg orally once daily for 3 days, or 2 g orally as a single dose for certain infections.
None Documented
None Documented
1.5-2.0 hours in adults with normal renal function; may be prolonged in hepatic impairment (up to 5-6 hours) but not significantly changed in renal disease.
Terminal elimination half-life of approximately 68 hours (range 35-96 hours), allowing once-weekly dosing for some indications.
Primarily hepatic (biliary) excretion of unchanged drug and metabolites; approximately 2-5% renal excretion of unchanged drug; 5-15% fecal elimination.
Primarily eliminated via biliary/fecal route (∼50-60% as unchanged drug); renal excretion accounts for ∼12% of the dose; minimal metabolism.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic